NVSNovartis PharmaceuticalsFinished
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (final count)
- Started
- Aug 19, 2020
- Main results expected
- Nov 7, 2024
- Fully finished
- Nov 7, 2024
- Results posted
- Nov 4, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1
Measured over: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04452877 · record last updated 2026-01-13 · checked 2026-11-09 15:47 UTC